Want to see SE:INIT full AI Analyst Report?
Top Page
Initiator Pharma A/S
(INIT)
Select Model
Select Model
Rating:45Neutral
Price Target:
kr2.00
▼(-12.66% Downside)
Action:Reiterated
Date:08/22/26
The score is primarily pressured by weak financial performance: no revenue, widening losses, high cash burn, and a deteriorating balance sheet that increases funding and dilution risk. Technicals are neutral (short-term stabilization but still below longer-term averages), providing only modest support. Valuation remains constrained by negative earnings and no dividend yield data.
Positive Factors
Focused Therapeutic Strategy
A focused therapeutic strategy can concentrate limited resources, development expertise and capital on a defined clinical need. Specialization may support clearer positioning and more efficient portfolio decisions than a broad, unfocused pipeline.
Negative Factors
No Commercial Revenue
The absence of revenue confirms that the company remains dependent on clinical development rather than operating cash inflows. Until a product is approved and commercialized, funding needs remain high and financial performance depends heavily on pipeline progress.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused Therapeutic Strategy
A focused therapeutic strategy can concentrate limited resources, development expertise and capital on a defined clinical need. Specialization may support clearer positioning and more efficient portfolio decisions than a broad, unfocused pipeline.
Read all positive factors
Initiator Pharma A/S (INIT) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr163.60M
Dividend YieldN/A
Average Volume (3M)113.59K
Price to Earnings (P/E)―
Beta (1Y)0.75
Revenue GrowthN/A
EPS Growth-111.93%
CountrySE
Employees1
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.40
Shares Outstanding68,452,890
10 Day Avg. Volume97,709
30 Day Avg. Volume113,586
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.31
Price to Sales (P/S)0.00
P/FCF Ratio-7.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.63
Revenue Forecast (FY)N/A
Initiator Pharma A/S Business Overview & Revenue Model
Company Description
Initiator Pharma A/S is a clinical-stage life sciences firm dedicated to discovering therapeutic solutions for critical unmet medical needs affecting the central and peripheral nervous systems. Its development pipeline features several clinical-ph...
Initiator Pharma A/S Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
28
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -29.73M | -14.83M | -11.07K | -23.41K | -38.42K | -21.63K |
| EBITDA | -31.99M | -18.20M | -14.50K | -27.03K | -41.73K | -23.06K |
| Net Income | -27.92M | -14.01M | -12.93K | -22.87K | -38.45M | -21.06M |
Balance Sheet | ||||||
| Total Assets | 20.94M | 32.99M | 15.29M | 29.79M | 48.34M | 53.70M |
| Cash, Cash Equivalents and Short-Term Investments | 17.10M | 26.26M | 13.37M | 24.34M | 38.91M | 34.15M |
| Total Debt | 9.69M | 2.15M | 0.00 | 15.44M | 12.58M | 13.29M |
| Total Liabilities | 12.41M | 3.43M | 510.00K | 18.62M | 14.32M | 18.71M |
| Stockholders Equity | 8.53M | 29.56M | 14.78M | 11.16M | 34.02M | 34.99M |
Cash Flow | ||||||
| Free Cash Flow | -23.70M | -17.73M | -12.08M | -17.65M | -32.70M | -34.10M |
| Operating Cash Flow | -23.47M | -18.19M | -12.08M | -17.65M | -32.70M | -34.10M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -17.00K | 0.00 |
| Financing Cash Flow | 35.76M | 31.36M | 1.11M | 2.87M | 37.48M | 54.94M |
Initiator Pharma A/S Technical Analysis
Neutral
2.29
Price Trends
2.49
Negative
2.75
Negative
2.88
Negative
Market Momentum
-0.04
Positive
46.83
Neutral
32.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:INIT, the sentiment is Neutral. The current price of 2.29 is below the 20-day moving average (MA) of 2.45, below the 50-day MA of 2.49, and below the 200-day MA of 2.88, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 46.83 is Neutral, neither overbought nor oversold. The STOCH value of 32.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:INIT.
Initiator Pharma A/S Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
48 Neutral | kr192.20M | -8.14 | -56.09% | ― | ― | 14.10% | |
48 Neutral | kr131.45M | -2.71 | -81.23% | ― | -4.02% | 35.86% | |
45 Neutral | kr163.60M | -3.98 | ― | ― | ― | -111.93% | |
45 Neutral | kr166.77M | -3.89 | -17.52% | ― | -100.00% | 20.96% | |
43 Neutral | kr129.43M | -12.47 | -93.01% | ― | ― | 54.60% | |
41 Neutral | kr135.22M | -2.68 | 245.07% | ― | -38.46% | 9.02% |
* General Sector Average
SE:INIT
Initiator Pharma A/S
2.39
-1.56
-39.49%
SE:ALZ
Alzinova AB
0.82
-0.55
-39.93%
SE:XINT
Xintela AB
0.16
-0.22
-58.68%
SE:ELIC
Elicera Therapeutics AB
2.88
-3.78
-56.78%
SE:ACTI
Active Biotech AB
4.91
-8.47
-63.30%
SE:NXTCL
NextCell Pharma AB
1.04
-0.07
-6.31%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.